<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Three patients, one with Philadelphia (Ph) chromosome positive <z:hpo ids='HP_0011010'>chronic</z:hpo> myelocytic <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>) and two with primary acquired <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), have been identified to have a t(3;21)(q26;q22) </plain></SENT>
<SENT sid="1" pm="."><plain>In the patient with <z:mp ids='MP_0005481'>CML</z:mp>, the t(3;21) was detected only in the <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast phase</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>The t(3;21) as the sole abnormality appeared at presentation of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> [<z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>)] in one patient and remained as such when progression to <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e> in transformation (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t) occurred </plain></SENT>
<SENT sid="3" pm="."><plain>The other patient with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> had the t(3;21), in addition to other changes, during the progression of the disease </plain></SENT>
<SENT sid="4" pm="."><plain>Thus, t(3;21) may characterize myeloid crises of clonal hematopoietic stem cell disorders (HSCD) and indicates a poor prognosis </plain></SENT>
<SENT sid="5" pm="."><plain>As a primary cytogenetic event it may be also involved in the genesis of <z:hpo ids='HP_0002863'>myelodysplasia</z:hpo> with subsequent leukemic transformation </plain></SENT>
</text></document>